Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 52-Week High - Time to Buy?

Key Points

• Teva shares reached a new 52-week high of $41.69, up from a prior close of $39.25, with the stock trading above both its 50-day and 200-day moving averages.
• Analyst sentiment is largely positive: 12 analysts rate Teva a Buy and one rates it Hold, producing a consensus “Moderate Buy” rating and a $44.67 price target. Recent targets range from $48 at UBS to $55 at TD Cowen.
• Teva reported quarterly revenue of $4.14 billion and earnings of $0.02 per share, while insiders sold approximately $14.6 million of stock in the last quarter; institutional investors own 54.05% of the company.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) shares reached a new 52-week high during trading on Friday. The company traded as high as $41.69 and last traded at $41.2480, with a volume of 2502662 shares. The stock had previously closed at $39.25.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on TEVA. Oppenheimer started coverage on Teva Pharmaceutical Industries in a report on Wednesday, September 23rd. They set an "outperform" rating and a $50.00 price target on the stock. Wall Street Zen lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a "buy" rating in a research report on Friday, September 4th. TD Cowen began coverage on Teva Pharmaceutical Industries in a research report on Thursday, October 1st. They set a "buy" rating and a $55.00 price target for the company. Finally, Weiss Ratings lowered shares of Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, September 8th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.67.

Teva Pharmaceutical Industries Stock Performance

The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The stock has a market cap of $48.32 billion, a PE ratio of 69.07, a PEG ratio of 3.61 and a beta of 0.89. The stock has a fifty day simple moving average of $37.52 and a two-hundred day simple moving average of $34.43.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The company had revenue of $4.14 billion during the quarter. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of the business's stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total transaction of $285,236.70. Following the sale, the insider directly owned 8,500 shares in the company, valued at approximately $330,225. The trade was a 46.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 374,959 shares of company stock valued at $14,644,285 in the last quarter. 0.54% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. QRG Capital Management Inc. grew its stake in Teva Pharmaceutical Industries by 17.0% in the 2nd quarter. QRG Capital Management Inc. now owns 89,078 shares of the company's stock valued at $3,018,000 after buying an additional 12,925 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in shares of Teva Pharmaceutical Industries by 7.1% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company's stock worth $248,000 after purchasing an additional 483 shares during the period. Bullseye Investment Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $68,000. Sequoia Financial Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 12.5% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 190,940 shares of the company's stock valued at $6,469,000 after purchasing an additional 21,240 shares during the period. Finally, National Pension Service boosted its stake in Teva Pharmaceutical Industries by 4.9% during the 2nd quarter. National Pension Service now owns 2,406,013 shares of the company's stock valued at $81,516,000 after purchasing an additional 112,357 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars.

Teva's portfolio includes medicines for conditions affecting the central nervous system, respiratory system and other therapeutic areas. Its branded and specialty products include treatments such as Copaxone for multiple sclerosis, Austedo for movement disorders, Ajovy for migraine prevention and Uzedy for schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.